Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Adipokine grem2 as a drug target in the treatment of obesity

A technology for adipokines and obesity, applied in biological testing, chemiluminescence/bioluminescence, analysis by making materials undergo chemical reactions, etc., can solve problems such as little known biological functions of GREM2

Active Publication Date: 2018-03-30
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported that GREM2 is related to bone formation, but little is known about the biological function of GREM2, especially in energy metabolism.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adipokine grem2 as a drug target in the treatment of obesity
  • Adipokine grem2 as a drug target in the treatment of obesity
  • Adipokine grem2 as a drug target in the treatment of obesity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0017] 1. Detection of serum GREM2 levels in normal controls and obese patients

[0018] In this study, from June 2013 to August 2014, 167 obese patients who met the indications and were treated in this hospital were enrolled in the obesity clinic of the Department of Endocrinology, Ruijin Hospital, and 147 normal volunteers were recruited at the same time. . The inclusion criteria for obese patients are: BMI ≥ 30.0kg / m2, aged between 14-34 years old. Exclusion criteria: 1) Secondary obesity; 2) Application of endocrine hormone drugs (including oral contraceptives, glucocorticoids); 3) Taking hypoglycemic or blood lipid-lowering drugs; 4) Pregnant or lactating patients; 5) Severe patients with abnormal liver and kidney function; 6) patients with neurological or mental diseases.

[0019] In addition, we recruited 147 normal volunteers from the students of Shanghai Jiao Tong University School of Medicine. The inclusion criteria for normal recruitment are: BMI ≤ 23.0kg / m2, age...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine preparation, and in particular relates to the application of adipokines GREM2 in the preparation of medicines for treating obesity. By detecting the serum GREM2 level, it was found that the serum GREM2 level of obese patients was significantly higher than that of normal weight controls. Through expression profiling analysis, it was found that the secreted factor GREM2 was mainly expressed in visceral adipose tissue. Further in vitro primary adipocyte induction experiments found that overexpression of GREM2 can significantly inhibit the ability of adipocytes to differentiate into beige fat, inhibit the function of mitochondria, and significantly reduce the expression of brown fat-specific gene UCP1. This effect is mediated by inhibiting the BMP / Smad signaling pathway. The present invention finds for the first time that the secretion factor GREM2 is mainly derived from mature white fat cells, and that GREM2 is involved in the browning process of white fat. Therefore, GREM2 can provide a new drug target for the clinical treatment of obesity.

Description

technical field [0001] The invention belongs to the technical field of medicine preparation, and in particular relates to the application of adipokines GREM2 in the preparation of medicines for treating obesity. Background technique [0002] The prevalence of obesity is increasing year by year worldwide, and studies have reported that 1 / 3 of the people in the United States are already obese. Obesity is an important risk factor for many chronic non-communicable diseases such as type 2 diabetes, cardiovascular disease and certain tumors, which seriously endangers human health. Recently, the FDA approved two new weight-loss drugs aimed at reducing energy intake by suppressing appetite. Since many appetite-suppressing weight-loss drugs had relatively serious side effects in the past, their application prospects are also not optimistic. Therefore, increasing energy consumption to intervene in obesity has attracted more and more attention from clinicians and basic researchers, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N21/76G01N30/02G01N33/66
Inventor 宁光洪洁王计秋刘瑞欣杨明兰
Owner RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com